the worst offense I have seen on iHub was when the Moderator pumped the stock.

let's face it -- iHub is a den of thieves. Nothing will ever change that, unless the SEC shuts it down completely. But we all know the SEC will never do that, so, welcome to the oil towns of North Dakota.

CIT is not being developed anywhere. In 2010 there was some press about CIT and NuVax, but NuVax is currently dormant, with no money and no employees.

The FACTS are here in the SEC filing if anyone is interested in FACTS:

https://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm

Radient wrote off CIT as worthless on Dec 31, 2010. They then tried to develop Dr. Chang's newer technology from the University of Florida. When they got more financing in 2011 they did not spend any of it on CIT, and when they ran out of money in 2011 NuVax ceased operations.

Page 11 of the 10K:

"Due to the following conditions at December 31, 2010, we decided to impair the remaining balance of our CIT asset:
· Lack of any potential future revenue;
· Lack of future cash flows;
· High cost of future clinical studies; and
· Limited time remaining on the patent."

"In January 2011, NuVax signed four exclusive license agreements with the University of Florida Research Foundation, Inc. (“UFRF”), for the development and marketing of a cancer therapeutic product developed by the UFRF. In July 2011, the UFRF terminated the agreements due to lack of funding.

On August 29, 2011, due to lack of funding and activity, Umesh Batia resigned as CEO and Director of NuVax. As of the date of this report, we have not generated any revenues and incurred license termination fees expenses for NuVax. Until we can complete funding for NuVax, we will continue to have minimal activity in NuVax."

No news since then means NuVax is still dormant. To suggest that "lack of news" means NuVax is secretly operating again is absurd.

As for SRL: SRL never had an agreement or license with Radient or AMDL. There is no evidence that SRL is doing anything with CIT, DR-70, onko-sure, or NuVax. SRL sold some DR-70 tests they acquired from Guar Diagno, selling them at half price of $44 USD, but that supply ran out long ago and SRL did not order more tests -- instead, they stopped selling the tests.

vester_guy, good DD about NO MERGER.

I'm glad to see that you now understand that Radient and Provista PR's from 2010 and 2011 are old news and no longer mean anything.

When William said that he was taking ProvistaDX Public in 2011, he was CEO of Provista. William then left that position, replaced by Reese. It does not matter what William said in 2011 when he was CEO of Provista because he hasn't been CEO for several years.

Reese, the new CEO of Provista, will now assume the task of taking ProvistaDx public. ProvistaDx abandoned LC Sentinel and DR-70 in early 2013. ProvistaDx will go public, but RXPC will not be part of that in any way.

NuVax is not operating.

NuVax was basically Bhatia and Chang, and they left when Radient stopped paying them. Nobody is currently doing any work at, or for, NuVax, and Radient has no money to start up NuVax again.

Read the 2011 10K for insight.
https://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm

page 37:

"On August 29, 2011, due to lack of funding and activity, Umesh Batia resigned as CEO and Director of Nuvax. As of the date of this report, we have not generated any revenues and incurred license termination fee expenses for NuVax. Until we can complete funding for NuVax, we will continue to have minimal activity in NuVax."

What does it mean to be VALID with the FDA?

DR-70 is still "valid" because it's in their database as a device that was once cleared for marketing. DR-70 is not currently cleared for marketing though.

Even if it was still cleared, DR-70 won't be an asset of Radient after the last patent expires in five weeks.

Nobody has been predicting bankruptcy since 2006. In 2006, This company didn't look bad -- they had just received FDA clearance and a year later they acquired Jade as a subbsidiary. I have been predicting bankruptcy since 2009, though, because (a) Jade revolted in 2009 and (b) it was obvious that DR-70, even with its FDA clearance, would never be profitable. It's useful for clinical studies of drugs and other tests, but it is not profitable.

I think this company *would* have filed for bankruptcy in 2010 if Biomedreports hadn't come along. Biomedreports said some wildly optimistic and 100% false things about this company in 2010 and 2011, causing the PPS to soar close to $50 and allowing Radient to do some financing that otherwise would not have been possible.

Today, the PPS is 0.0001 and the company is shut down. I think my bankruptcy prediction was pretty close -- far closer than predictions of mergers and financial success.

The 2011 lenders loaned Radient money in 2011 because Radient told them (and the world) they had $20 million equity as collateral and $10 million sales coming in India and were conducting a collaberative study with the Mayo Clinic and were goign to "monetize" an exciting new subsidiary named NuVax. Today, we know that was all false, but I guess the lenders had no way of knowing the truth in 2011.

There's no patent update.

You didn't follow blackpanther's link - nothing was updated 02-24-2014. blackpanther means that the FDA page for DR-70 was updated yesterday 4/21/2014, and goldseeker is saying "that means nothing, they all are." just like the WIPO site, I might add.

here, let me save you some time: here's BP's link for DR-70:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn_template.cfm?id=k072901

click the device, go to the page with the date:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID=2784

DR-70 is k072901, let's just subtract 1 from that, k072900, and check to make sure goldsweeker is correct:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn_template.cfm?id=k072900

click that device: yep, same date of 4/21/2014:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID=5387

Etc Etc Etc

And notice that DR-70 is currently not cleared by the FDA for anything, including CRC, because nobody paid the FDA filing fees, as goldseeker found many months ago.

and also notice that it's not currently cleared by the FDA

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm

"The 2011 lenders saw an opportunity for the FUTURE with Radient..."

Because Radient told them they had $20 million equity, $10 million upcoming 2011 revenues, and two assets they were going to monetize: NuVax and Jade.

Within six months, the lenders knew that Radient had a deficit, not equity, the $10 million 2011 revenues were grossly exaggerated, and NuVax and Jade were not going to be monetized. And, by the way, Radient defaulted on EVERY LOAN.

The lenders knew at that point that there WAS no future with Radient. Hence the lawsuits and the debt-to-equity swaps and today, how much debt outstanding?

"They would not agree to pay out 2.5 million dollars to shysters if the company did not have valuable properties with a clear plan of putting them to good use."

Who are you calling a shyster? And your statement has a logical flaw -- the main reason to settle is because you don't want to spend time and money to go to court and run the risk of having to pay a much larger settlement.

You think Radient has "valuable properties? " name one.

"The Creeping Takeover is being executed thru lender debt conversion to shares?" no more shares. At .0001 or less, that converted about $400,000 of the $20 million debt.

"Clandestine manner?" the MJ rumor showed that there is a bottomless pit of shares on the ASK aat or under 0.0005. That killed the MJ rumor. Any objective investor who has followed the trading volumes and corresponding bid/ask prices knows this.

"Select RXPC detractors have created disinformation?" SEC filings constitute disinformation?

"When the Takeover is announced, the New Owners will most likely swap Provista shares for your RXPC stock. Resist closing your position out- hold your new shares until the IPO actually occurs."

Who are you talking to? Accordign to "investigative longs," 85% of all shares are held by lenders and the takeover group. Who are you preaching to here?

"It proves The Lung Cancer Test (LC SENTINEL/DR-70 will be in the pipeline of GCDX..."

nobody is refuting the claim that GCDx will try to sell DR-70 as a lung cancer test if GCDx ever gets funding. But they can do that in five weeks without any involvement with RXPC.

When I point out there isn't even a shred of proof that any entity is merging with, taking over, or acqwuiring RXPC, your response is "Of course not! it's secret! That's my proof!"

"Why would the 2011 lenders put 8 million into Radient?"

Because Radient said they had $20 million equity in Jade, $10 million revenues coming in India, and plans to spinoff Jade and NuVax for big bucks.

The real question in my mind is: why would anyone lend money to Radient in 2011 after seeign that Radient defaulted on every 2009 and 2010 loan and lost $85 million in 2010 and was generating revenues of only 5% of operating costs?

"..That is irrelevant about Jade.."

I said "after Jade revolted, ....." it's a secondary clause in my sentence. I am talking about Radient not Jade.

I am not going to waste our tinme offering an opinion abotu who owns the 5 billion shares. the fact is: no Schedule 13's. No reporting entities hold 5% so who cares who is holdign the bag here?

"You don't want to show assets when you are in a middle of a class action suit now do you?"

Explain what you mean. Are you saying that Radient thinks CIT is actually NOT worthless, but they wrote it off to benefit in a class action settlement?

"Look at the volume on February 24 over 700 million..The 24th of March..Over 300 million in volume..24th of April????"

volume in Feb 2013 was due to the SRL hype -- but have you noticed that SRL stopped selling the test? Volume in Feb and March 2014 was the MJ rumor, aided by the lenders and/or lawyers dumping into the volume. So if you want volume on April 24th, better start a twitter rumor, and you'll need something better than this merger nonsense, IMO.

Schedule 13's must be kept current. If you file one and hold the shares through your next reporting period, you must file another. You don't file a 13 because you just ACQUIRED 5%, you file a 13 because you HAVE 5%. Just look at Ironridge's 13's.

I absolutely do NOT think Provista will spend even a penny on GCDx. GCDx is not affiliated with Provista. The Provista hsareholders would storm the castle if Provista spent that funding on GCDx, IMO. That is too ridiculous to discuss further. Anyone who thinks that is even a possiility should contact Provista and clarify their intentions, plans for, and use of DR-70.

vester_guy, forget the "why would..." tactic of debate -- that is all conjecture and just clutters this MB. You want to stick to the facts, right?

I posted a link to ProvistaDX pipeline page. No LC Sentinel. no lung cancer test.

Your opinion is, RXPC has been involved in a creeping takeover or creeping backdoor merger since 2010. You believe that, fine.

I think that is absurd.

Hopefully, time will prove one of us right, soon.

vester_guy, you said:

"Lake your last four posts have to proven..."

what do you want proof of? Just ask. I've posted my proof several times but I'm happy to do it again.

proof that ProvistaDx does not have LC Sentinel in their pipeline?

http://www.provistadx.com/provistaDx-Pipeline.html

proof that Radient's gross revenues were only 5% of their operating costs after Jade revolted, and they lost $85 million in 2010 and $85 million in 2011?

https://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm
https://www.sec.gov/Archives/edgar/data/838879/000114420411032218/v218209_10k.htm

Proof that the Radient/Provista 2010 LOI was extended to 12/31/2010 (and not beyond)?

http://www.biospace.com/News/radient-pharmaceuticals-and-provista-life-sciences/197802

Proof that a LOI is not a binding contract? Just read the legal LOI instead of reading PR’s about the LOI. Since nothing happened by 12/31/2010, tha LOI terminated.

https://www.sec.gov/Archives/edgar/data/838879/000095012310064927/a56670exv10w1.htm

Proof that CIT was written off as worthless? See the 2011 10K above.

vester_guy, you said:

"William doesn't have enough funding to go alone with GCDX..You admitted that he couldn't raise mony..You are right, he raised it through Provista DX. "

Provista's Form D's prove that to be 100% wrong. They specify that the money will NOT be used for a takeover or merger. That money can only be used for ProvistaDx, not for merging with or taking over ANY other company.

Rewese split off the weaker technologies and companies for a reason. Reese is not going to apply any of that money to developing or selling DR-70 and that is all GCDx is -- a business plan to sell DR-70 on the internet.

Radient would not benefit in any way from UNI selling DR-70 after Radient's patent expires. That statement makes no sense.

The LOI you're talking about expired on 12/31/2010 -- we proved that. Besides, a LOI is never binding. the I stands for "Intent." a LOI is not a contract -- it's a marketing ploy, like a PR.

You claim to have bought, and own, a billion shares. That alone is proof that there is no takeover. Under NO circumstances would a takeover group allow you to accumulate that many shares. The best evidence against a takeover is right there, under your nose.

NO you are confused. Provista Dx does not have LC Sentinel. You are looking at old information on outdated internet pages.

It is that simple, wolfie. This is not my opinion, it is a FACT, Provista Dx is not doing anything with LC Sentinel or DR-70 and they never will.

Read the definition of NDA, wolfie. It would not prevent UNI from manufacturing or selling the test -- it would merely prevent them from telling someone else how to do it.

The PPS proves me right, wolfie. There is no merger. The only question remaining is: Will RXPC stagger along as a zombie forever like MacLellan's other company AXMP, or will RXPC file for bankruptcy like MacLellan's other companies Edgewater Foods and PortaCom?

vester_guy, the 1:25 R/S didn't burn you. If this company was a healthy successful company, that would not have mattered.

What burned you was believing Garza and believing the CEO's press releases and believing Silvani. If you had just read the SEC filings you would have seen the truth: losing Jade was a death knell. Without Jade, this company could only generate enough gross revenues to cover about 5% of operating costs.

That is an unsustainable business model. To put it mildly.

Even in the remote possibility that some entity was considering a merger with or takeover of Radient, a quick glance at the SEC filings would put an end to that plan quickly. It's cheap to license DR-70 and try to sell it, and then if you fail, oh well. But to buy the company and then fail to sell it would be disastrous to the acquiring entity.

Companies like Astellas and Fortis don't become successful by buying zombie biotechs. Provista saw that DR-70 was a failure and kicked it to the curb in 2011, and it looks like they kicked Gartner to the curb at the same time, although we will never know exactly what happened there.

But if you stop looking in the rear-view mirror and look at Radient today, you see a non-operational shell with a lot of debt and no assets. Doesn't take a genius to realize that there will be no merger or takeover.

NDA just means that UNI can't share Radient's information with anyone else.

There is no non-compete clause that would prevent UNI from selling DR-70 after Radient's last patent expires in five weeks. The new UNI contract says quite specifically that UNI can continue to manufacture and sell DR-70 after that last patent expires.

Incidentally, the agreement between UNI and Radient is not an LOI as you are stating here. LOI stands for Letter of Intent. Radient and UNI have a CONTRACT. And there should be no misinterpretation of the clause that allows UNI to manufacture and sell DR-70 after Radient's last patent expires.

Whether GCDx and Amarantus and MemoryDx merge or buy each other out is not important to this message board.

Radient is not being included in any merger, buy out, acquisition, or takeover. This is a Radient message board.

Radient has no assets. Companies with no assets don't get merged with, taken over, acquired, or bought out. Add Radient's debt and the idea becomes even more ludicrous.

The new CEO of Provista discarded those companies and technologies, including Radient's blood test, for a reason. Then he got financing for Provista. You suggest that he will now bring all those discarded companies and technologies back together under Provista?

Provista shareholders and financers would never allow that to happen.

Radient is as different from Microsoft as night differs from day.

Lesson has not started, apparently.

Nice post, Goldseeker.

The current "investigative longs" don't want to hear that, but any new potential investors will read your post and understand what truly happened with this company.

I could add: In 2011, two years after Jade revolted, Radient still listed its "Jade Holdings" on their balance sheet as a $20 million asset. They used that balance sheet to get loans to pay off the previously defaulted loans and fund future projects and salaries.

Then the SEC told Radient to either prove that their Jade holding was worth something or remove it from the books. Radient removed it from the books.

Suddenly, Radient had a shareholder deficit instead of shareholder equity. Then they defaulted on the final round of loans after making just two payments. Then they were delisted. Then they increased the A/S to 5 billion and proceeded over the next few years to issue all those shares.

After Jade revolted, operating costs during the "operating years" were about $2 million per quarter, offset by only about $200,000 gross revenues per quarter at best. The company reported $85 million losses for each of 2010 and 2011 and then stopped filing financial statements.

They vacated their office and manufacturing facility sometime in 2013. Their last patent expires on June 3rd 2014, at which time their only asset will be a patent for CIT which they wrote off as worthless in 2011. All the officers left the company except the CEO, and he brought in an old friend from a previous bankrupt endeavor, PortaComm, for reasons unkown, so now there are two officers and zero employees.

These are the facts. Not debatable, not disputable, all documented in the SEC filings. Nobody knows how much the current debt is, but $20 million seems a safe estimate.

The rumor of a merger or takeover is fascinating in its absurdity, IMO. A company that has no assets is not a takeover or merger candidate, even in the wildest turmoil of Wall Street.

No confusion.

The roles of Memory Dx, GCDx, RXPC, and ProvistaDx are not only CURENTLY separate, they are FOREVER separate, with the possible exception that Gartner might do something to combine MemoryDx and GCDx.

But if he does, RXPC and ProvistaDx will not be involved in any way. And what would be the point of combining MemoryDx and GCDx? MemoryDx had one asset and they licensed it away.

Fax Radient? Are you kidding?

I tried calling GCDx and emailing GCDX several times in the past TWO YEARS but their voice mail box is always full, just like Radient's, and GCDx does not respond to emails either.

ProvistaDx is the entity that built the facility and did the financing and has the money, wolfie. Any other entity named Provista[fillintheblank] means nothing to me.

I don't care what Gartner is doing now. All I know is: he pitched GCDx at AZBio and didn't raise enough money to get the thing going.... He pitched GCDX on Fundable and raised $200...... and the GCDx website has been promising for two years to start selling the test "soon," but that website is a ghost town.

I am not looking for ALS or AMBS or MemoryAnything. they are not related to RXPC or involved with RXPC in any way. We are talking about RXPC here. However, I do see that they registered the domain for MemoryDx on GoDaddy years ago but never put the site online. Why is that?

If there is an India or Asia market, UNI will meet its needs.

That won't help RXPC. Their patent expires in five weeks and after that time, UNI can manufacture and market the test in India and Asia without paying Radient a penny. Since Radient has no manufacturing facility anywhere, and in fact doesn't even have an office anywhere, I fail to see how an Asia market would affect Radient in any way.

SRL has no expansion plans. They merely bought some test kits from Guar Diagno when Guar Diagno failed to sell them. SRL sold those kits for half price in 2013 and today SRL is not involved with Radient, DR-70, or onko-sure.

Investigative longs know Radient's Tustin offices were vacated last year? Good to hear.

Do investigative longs know where Radient has an office now?

Do investigative longs know where Radient has a manufacturing facility now?

Please clarify.

I did call Provista, and I emailed them. John F stated specifically:

"For the LAST time, none of our products use DR-70 and we have no plans to use DR-70 in the future."

But don't believe a message board. Anyone who thinks for a SECOND that there is the slightest chance of Provista merging with Radient should contact Provista THEMSELVES and clear up that misconception.

I cannot call Radient because they do not answer their phone or listen to their voicemails.

I don't know what you mean by a "promotion pencil on the desk," but I do know that Radient does not have an office anywhere, and they do not have a manufacturing facility either. If they still own a desk, it's in storage somewhere.

Provista did not merely take their lung cancer test off their website. They stopped working on it completely. This is not debatable.

Gartner might own stock in Provista -- it makes sense that he has stock since he was once the CEO of the company. That does not mean he still works for Provista. You own stock in Radient, but do you work for them? No you do NOT because NOBODY does!

GCDx is not going to be a subsidiary of Provista. That is absurd. Provista would simply fund that project if they wanted anything to do with GCDx.

The 2011 interviews and 2010 LOI's are fun to read historically, but the current Provista is very different from the Provista that existed under Gartner. I think someone's rear view mirror needs cleaning. Otherwise, we might start seeing MacLellan quotes from 2009-2011 or Garza quotes from 2010-2011. We don't want THAT, now, do we?

True, let me rephrase then:

SRL ran out of kits they could SELL, and decided not to reorder.

Provista Diagnostics abandoned the lung cancer test.

Anyone who thinks ProvistaDx is working on a lung cancer test needs to contact Provista immediately and ask them. Don't believe what you read on message boards - do the DD and become empowered through knowledge.


Ask Provista if they are merging with Radient Pharmaceuticals. Tell Provista where you heard this rumor. Be specific. Time to put an end to this nonsense.

RXPC is not in flux. Nothing is on hold. Nobody is waiting on anything.

Radient has no business. Their last patent expires in five weeks, after which the company will have zero assets.

SRL is done with onko-sure, and after a couple years of poor revenues, UNI will probably be done with it too. But none of that affects RXPC in any way. RXPC is a zombie.

There is no takeover, no merger, no buyout -- Radient has no assets to take over, merge with, or buy out, other than a ticker listing on the bottom tier of the pinksheets where only zombies exist.

Now that the A/S is burned up and there are no more shares to issue, the chances for another pop on an MJ rumor of bird flu rumor or ebola rumor or WHATEVER rumor are slim, because the selling pressure is going to be even HEAVIER than it was for the MJ rumor a few weeks ago.

Those who bought the MJ rumor at .0002 and .0003 know what I'm talking about. Their finger is on the SELL trigger. They know the truth now.

Nobody is claiming that Provista never had the LC test.

Provista had that test, called LC Sentinel, when Gartner was CEO of Provista. LC Sentinel was Radient's DR-70 with a different name. When Gartner left Provista and Reese became CEO, Provista abandoned DR-70.

We're all using the Rear View Mirror now?

biomedreports in 2011, a LOI from 2010, Jade financing from 2006.... None of that is REMOTELY current DD on RXPC.

Biomedreports proved to be 100% wrong about everything concerning RPC and they not only stopped "covering" Radient in 2011 -- they stopped MENTIONING Radient in 2011. RPC is an embarrassment to biomedreports.

That 2010 LOI expired on Dec 31, 2010. Jade left Radient in 2009.

There is no current DD because this company is not doing anything other than appearing in court for a class action they are settling. Nothing else is happening here. So I applaud your use of the rear view mirror. It's enlightening. I welcome a discussion of Bhatia, Guar Diagno, and Jaiva Technologies. All three illustrate RPC's failures perfectly and prove that any merger/takeover that may have been started in 2011 or earlier are LONG dead.

Fine, I'm wrong, you said this board was started in 2006, You meant "the AMDL board was started in 2006."

You're wrong about the MB being created because of some Jade financing, I'm wrong about the date the RPC board was created, we are both wrong this time.

I don't think that changes the big picture.

SRL is not part of a blackout of news, intentional or otherwise. SRL simply ran out of DR-70 and decided not to order more, so they stopped selling it.

This message board was started for RPC when the company changed their name from AMDL to RPC in October 2006. Before that, there were AMDL boards. Nobody created a message board because of a Jade filing.

Nobody was a lender of Radient's in 2006. The previous CEO, Dreher, did not take out loans -- he did private equity placements ONLY.

The current CEO, MacLellan, took out loans instead of doing equity placements. Radient defaulted on EVERY ONE OF THOSE LOANS. In retrospect, the equity placements seemed like a better plan for this company.

The "takeover group" has been named as the lenders, Astellas, SRL, Fortis, Provista, and now Jade? That is just about as implausible as saying Bill Gates or JnJ is taking over Radient. The "takeover rumor" proponents might as well say it's Gates -- he has a lot more money than the others named so far.

Jade amounts to NOTHING as far as Radient is concerned.

Jade left Radient and took the equity with them. The reason RPC became RXPC is because the SEC forced the company to admit their Jade holding was worthless and Radient therefore had a shareholder deficit, not shareholder equity.

Today, Radient has no equity and their only remaining asset will be worthless in five weeks when the patent expires. RXPC is about the worst possible "investment" a person could make. I challenge anyone to find a stock that would be a poorer investment.

Easy to prove that the lenders do NOT own 34%.

If any of these entities in this list owned 9.99% of Radient, they would HAVE to file Schedule 13's and keep them current. These are reporting entities in this list.

The lack of current Schedule 13's is irrefutable proof that none of the lenders in this list own 5% or more.

There is no point discussing THIS further, unless someone can produce a current Schedule 13.

The interesting thing about a Schedule 13 is: if one existed, the reporting entity would have to reveal by the Schedule selected (D or G) whether it was part of a Takeover or Merger.

Let's look at Radient Pharmaceuticals on your "DD source."

www.bioportfolio.com/corporate/company/12463/Radient-Pharmaceuticals-Corporation.html

"Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and premium skin care products. "

First of all, they are not headquartered anywhere -- there is no physical office. If anything, they are headquartered wherever MacLellan is at the moment. Second, they haven't done anything with "skin care products" since they lost Jade in 2009. Finally, no mention of cancer? According to YOUR DD source, Radient no longer has a cancer test.

Conclusion: just because Bioportfolio.com has the word "lung cancer test" in their description of a company does NOT mean that company is working on a lung cancer test today. But, by all means, anyone who wants the final answer on this question should contact Provista and ask. They answer emails, they answer their phone, they have a physical location, THEY OPERATE.

Now, please look at section 10 of the filings in your link: "NO" is checked on all of them.

"10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Answer: NO

They cannot lie on this filing. That money cannot be used for a merger or takeover.

Overnight?

this merger supposedly started in March 2011. I hardly think THREE YEARS is "overnight."

Your statements contradict mine. They also contradict the court documents, Provista's website, Provista's SEC filings, and the only published versions of that LOI.

So I leave it up to the readers to decide whom to believe.